KRAS G12V

Assets acting on this target.

Class
KRAS G12V-selective RAS(ON) inhibitor (tri-complex inhibitor)
Pathway
RAS/MAPK signaling

KRAS is a small signaling protein that acts as a molecular switch, cycling between an inactive, GDP-bound state and an active, GTP-bound state. In its active state it triggers the RAS/MAPK pathway, a signaling cascade that instructs cells to grow and divide. The G12V mutation replaces a glycine with valine at position 12, impairing the protein's ability to switch itself off and locking it predominantly in the active, growth-promoting conformation. This sustained signaling drives uncontrolled proliferation in a range of cancers carrying this mutation. Because G12V lacks the reactive cysteine that some other KRAS mutants (such as G12C) offer as a covalent drug-binding site, inhibitors must instead target the active, GTP-bound form of the protein directly. Tri-complex inhibitors achieve this by simultaneously engaging KRAS and a cellular chaperone protein, forming a three-part assembly that blocks the mutant protein from interacting with its downstream signaling partners. This class is often described as a RAS(ON) inhibitor, distinguishing it from earlier approaches that only worked on the inactive state. The broader rationale is to shut down a persistently active oncogenic driver at its source, rather than downstream in the pathway.

By indication

Related mechanisms

KRAS G12V drugs compared

2 drugs, stage by indication
2 drugs acting on KRAS G12V: developer, modality, furthest stage and stage in each indication. Furthest stage first.
DrugDeveloperModalityFurthest stageStage by indication
AFNT-211Affini-T Therapeutics, Inc.cell therapyPhase 1/2Phase 1/2 in Non-Small Cell Lung Cancer
RMC-5127Revolution Medicinessmall moleculePhase 1Phase 1 in Non-Small Cell Lung Cancer

← all mechanisms